Precipio Launches New 1-Step Technology for all HemeScreen Assays
16 août 2022 11h00 HE
|
Precipio, Inc.
NEW HAVEN, Conn., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces the launch of its second generation of HemeScreen panels. Precipio’s...
Toni-Ann Mills Joins Precipio’s Products Division to Lead Channel Partner Training, Learning & Development
10 août 2022 10h00 HE
|
Precipio, Inc.
NEW HAVEN, Conn., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), welcomes Toni-Ann Mills as the Company’s Senior Director for Learning &...
Precipio Announces Second Quarter Shareholder Update Call
08 août 2022 10h00 HE
|
Precipio, Inc.
NEW HAVEN, Conn., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q2-2022 shareholder update call on Monday, August 15th at...
Precipio to distribute HemeScreen® through Fisher Healthcare channel
20 juil. 2022 10h30 HE
|
Precipio, Inc.
NEW HAVEN, Conn., July 20, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced that it has entered into an agreement with Fisher Healthcare,...
Precipio requests that all Stockholders that have not yet voted, proceed to cast their vote
14 juin 2022 14h00 HE
|
Precipio, Inc.
NEW HAVEN, Conn., June 14, 2022 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ:PRPO), announced today that the Company’s 2022 Annual Meeting of Stockholders was adjourned...
Keith Meadors Joins Precipio to Lead its Products Division
13 juin 2022 11h00 HE
|
Precipio, Inc.
NEW HAVEN, Conn., June 13, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company, Precipio, Inc. (NASDAQ: PRPO), today announced that Keith Meadors has joined Precipio as its Senior Vice...
Precipio Receives CE-IVD Certification to Market Multiple HemeScreen® Panels in Europe
24 mai 2022 10h30 HE
|
Precipio, Inc.
NEW HAVEN, Conn., May 24, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company, Precipio, Inc. (NASDAQ: PRPO), today announced that it has received CE-IVD approval for sale of its...
Precipio Signs First IV-Cell Customer Agreement
10 mai 2022 10h30 HE
|
Precipio, Inc.
NEW HAVEN, Conn., May 10, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that American Oncology Network (AON) of Fort Myers, Florida,...
Precipio customer American Oncology Network (AON) selected to present HemeScreen® technology case study at Industry leading clinical laboratory conference
26 avr. 2022 10h00 HE
|
Precipio, Inc.
NEW HAVEN, Conn., April 26, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), is excited to announce its participation and the presentation of HemeScreen,...
Precipio Announces 2021 Fourth Quarter and Year-End Shareholder Update Call
22 mars 2022 18h00 HE
|
Precipio, Inc.
NEW HAVEN, Conn., March 22, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q4-2021 and year end shareholder update call on Monday,...